Table 1 |
||||
|
CTX levels in different groups |
||||
| CTX isoform |
||||
|
|
||||
| Subjects |
αL CTX/Cr |
βL CTX/Cr |
αD CTX/Cr |
|
|
|
||||
| Premenopausal patients |
Mean ± standard deviation |
3.65 ± 1.41 |
5.74 ± 3.46 |
1.75 ± 0.94 |
| Postmenopausal patients |
Mean ± standard deviation |
8.39 ± 3.01 |
13. 6 ± 3.9 |
3.62 ± 1.08 |
| P, U testa |
< 0.001 |
< 0.001 |
< 0.001 |
|
| T scorea |
3.4 |
2.3 |
2.0 |
|
| Normocalcemic breast cancer patients without bone metastases |
Mean ± standard deviation |
10.2 ± 6.23 |
12.7 ± 11.3 |
4.73 ± 4.14 |
| P, U testb |
Not significant |
Not significant |
Not significant |
|
| Z scoreb |
0.60 |
-0.23 |
1.03 |
|
| Normocalcemic breast cancer patients with bone metastases |
Mean ± standard deviation |
22.6 ± 24.8 |
24.6 ± 18.4 |
7.95 ± 9.11 |
| P, U testc |
< 0.01 |
< 0.01 |
< 0.05 |
|
| Z scorec |
2.00 |
1.01 |
0.76 |
|
| Hypercalcemic breast cancer patients with bone metastases |
Mean ± standard deviation |
35.1 ± 27.8 |
38.0 ± 23.7 |
11.3 ± 10.2 |
| P, U testc |
< 0.01 |
< 0.01 |
< 0.05 |
|
| Z scorec |
3.41 |
2.24 |
1.59 |
|
|
|
||||
|
Concentrations are provided as μmol/mol. αD = D-aspartyl peptide; αL = L-aspartyl peptide; βL = L-isoaspartyl peptide; Cr, creatinine; CTX, crosslinked C-telopeptide of type I collagen. aVersus premenopausal patients. bVersus postmenopausal patients. cVersus normocalcemic breast cancer patients without bone metastases. |
||||
|
Andreas Compare Cloos et al. Breast Cancer Res 2003 5:R103 doi:10.1186/bcr607 |
||||
